ArticleRSC advances2025
Design and synthesis of Indol-PHOX: a new class of modular phosphine-oxazoline ligands for palladium-catalyzed enantioselective decarboxylative allylation.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel class of chiral and modular P,N-ligands featuring an indolizine core (Indol-PHOX) has been developed, successfully enabling the highly efficient and enantioselective palladium-catalyzed decarboxylative allylation of various α-fluoro-β-ketoesters to access valuable α-allyl-α-fluoro ketones with yields up to 99% and 96% ee. This process exhibits a broad substrate scope, demonstrating good tolerance for both electron-withdrawing and electron-donating groups, as well as substitution patterns of the substrates. The reaction is scalable to the gram level, and subsequent post-functionalization reactions proceed successfully without erosion of enantiopurity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.